Natixis Advisors’s Zimmer Biomet ZBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.6M Buy
116,975
+4,130
+4% +$379K 0.01% 663
2025
Q4
$10.1M Buy
112,845
+16,210
+17% +$1.54M 0.01% 649
2025
Q3
$9.52M Buy
96,635
+15,402
+19% +$1.53M 0.01% 676
2025
Q2
$7.41M Buy
81,233
+4,931
+6% +$477K 0.01% 724
2025
Q1
$8.64M Buy
76,302
+4,920
+7% +$526K 0.02% 682
2024
Q4
$7.54M Buy
71,382
+7,731
+12% +$830K 0.01% 718
2024
Q3
$6.87M Buy
63,651
+12,602
+25% +$1.38M 0.01% 748
2024
Q2
$5.54M Sell
51,049
-15,673
-23% -$1.85M 0.01% 768
2024
Q1
$8.81M Sell
66,722
-84,103
-56% -$10.5M 0.02% 644
2023
Q4
$18.4M Buy
150,825
+6,204
+4% +$692K 0.05% 389
2023
Q3
$16.2M Sell
144,621
-63,101
-30% -$8.01M 0.05% 379
2023
Q2
$30.2M Buy
207,722
+27,586
+15% +$3.75M 0.09% 233
2023
Q1
$23.3M Buy
180,136
+18,573
+11% +$2.33M 0.08% 261
2022
Q4
$20.6M Buy
161,563
+41,645
+35% +$4.83M 0.08% 287
2022
Q3
$12.5M Buy
119,918
+11,573
+11% +$1.27M 0.05% 379
2022
Q2
$11.4M Sell
108,345
-62,013
-36% -$7.36M 0.05% 409
2022
Q1
$21.8M Buy
170,358
+30,193
+22% +$3.64M 0.08% 261
2021
Q4
$17.3M Sell
140,165
-13,501
-9% -$1.77M 0.07% 318
2021
Q3
$21.8M Sell
153,666
-15,080
-9% -$2.22M 0.09% 232
2021
Q2
$26.3M Buy
168,746
+50
+0% +$8.1K 0.12% 192
2021
Q1
$26.2M Buy
168,696
+19,379
+13% +$3M 0.14% 181
2020
Q4
$22.3M Buy
149,317
+22,829
+18% +$3.22M 0.13% 190
2020
Q3
$16.7M Sell
126,488
-8,460
-6% -$1.11M 0.11% 221
2020
Q2
$15.6M Buy
134,948
+10,741
+9% +$1.24M 0.1% 227
2020
Q1
$12.2M Buy
124,207
+12,457
+11% +$1.63M 0.1% 232
2019
Q4
$16.2M Buy
111,750
+3,850
+4% +$531K 0.11% 211
2019
Q3
$14.4M Buy
107,900
+12,756
+13% +$1.65M 0.11% 208
2019
Q2
$10.9M Buy
95,144
+12,702
+15% +$1.49M 0.09% 243
2019
Q1
$10.2M Sell
82,442
-4,464
-5% -$507K 0.09% 254
2018
Q4
$8.75M Sell
86,906
-3,385
-4% -$381K 0.09% 252
2018
Q3
$11.5M Buy
90,291
+24,406
+37% +$2.9M 0.1% 222
2018
Q2
$7.13M Buy
65,885
+11,757
+22% +$1.28M 0.07% 345
2018
Q1
$5.73M Buy
54,128
+14,528
+37% +$1.69M 0.06% 390
2017
Q4
$4.64M Buy
39,600
+2,744
+7% +$310K 0.05% 444
2017
Q3
$4.19M Sell
36,856
-25,770
-41% -$2.97M 0.04% 486
2017
Q2
$7.81M Buy
62,626
+6,468
+12% +$767K 0.08% 279
2017
Q1
$6.66M Buy
56,158
+5,475
+11% +$621K 0.07% 335
2016
Q4
$5.08M Buy
50,683
+1,903
+4% +$204K 0.06% 396
2016
Q3
$6.16M Sell
48,780
-3,106
-6% -$384K 0.08% 312
2016
Q2
$6.06M Buy
51,886
+6,461
+14% +$731K 0.08% 305
2016
Q1
$4.7M Buy
45,425
+15,109
+50% +$1.46M 0.07% 362
2015
Q4
$3.02M Sell
30,316
-126,045
-81% -$12.3M 0.05% 486
2015
Q3
$14.3M Buy
156,361
+24,728
+19% +$2.48M 0.25% 78
2015
Q2
$14M Buy
131,633
+3,544
+3% +$392K 0.24% 88
2015
Q1
$14.6M Buy
128,089
+5,165
+4% +$589K 0.26% 77
2014
Q4
$13.5M Buy
122,924
+12,150
+11% +$1.28M 0.25% 76
2014
Q3
$10.8M Sell
110,774
-103,749
-48% -$10.2M 0.22% 100
2014
Q2
$21.6M Buy
214,523
+7,600
+4% +$742K 0.31% 53
2014
Q1
$19M Sell
206,923
-96,725
-32% -$8.91M 0.29% 62
2013
Q4
$27.5M Buy
303,648
+24,079
+9% +$2.08M 0.45% 22
2013
Q3
$22.3M Buy
279,569
+41,906
+18% +$3.3M 0.41% 29
2013
Q2
$17.3M Buy
+237,663
New +$17.8M 0.34% 42

Other funds holding ZBH

Natixis Advisors's ZBH Position: Q1 2026 in Review

Natixis Advisors increased its Zimmer Biomet (ZBH) stake by 3.7% in Q1 2026, buying an estimated $379K and bringing the position to 116,975 shares worth $10.6M. The position accounts for 0.01% of the portfolio, ranked #663.

Natixis Advisors first reported a position in ZBH in Q2 2013 and has held it in 52 quarters since. The position peaked at $30.2M in Q2 2023. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.

  • Natixis Advisors held 116,975 shares of Zimmer Biomet worth $10.6M as of Q1 2026.
  • Natixis Advisors bought 4,130 Zimmer Biomet shares in Q1 2026, an estimated $379K.
  • Zimmer Biomet made up 0.01% of Natixis Advisors's portfolio in Q1 2026, its #663 holding.
  • Natixis Advisors first reported a position in Zimmer Biomet in Q2 2013 and has held it in 52 quarters since.
  • Natixis Advisors's Zimmer Biomet position peaked at $30.2M in Q2 2023.
  • 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.

Based on Natixis Advisors's 13F filing for Q1 2026, filed 13 May 2026.